Afrezza Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Afrezza market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to a focus on improving patient adherence, an increasing preference for patient-centric treatments, the entry of new market players, advancements in rapid-acting insulin formulations, and enhancements in product efficacy.

The projected growth during the forecast period can be attributed to expansion into emerging markets, improvements in healthcare infrastructure, integration with continuous glucose monitoring (CGM) systems, a supportive regulatory environment, and increased awareness campaigns. Key trends expected in this period include direct-to-consumer (D2C) advertising, personalized diabetes care, advancements in inhaler technology, the development of alternative insulin delivery systems, and innovative solutions for diabetes management.

The increasing prevalence of diabetes is anticipated to drive the growth of the afrezza market in the near future. Diabetes, a chronic metabolic disorder, is characterized by elevated blood sugar levels resulting from insufficient insulin production, impaired insulin action, or both. Factors contributing to the rising incidence of diabetes include increasing rates of obesity, sedentary lifestyles, unhealthy diets, an aging population, urbanization, genetic predispositions, and improved awareness and diagnosis. Afrezza plays a critical role in diabetes management by rapidly controlling post-meal blood sugar spikes, helping to prevent complications and improve glucose regulation. For example, the Office for Health Improvement and Disparities reported in March 2024 that the percentage of individuals with type 1 diabetes in England receiving eight care processes at GP practices participating in the NDA rose to 43.8% in March 2023, up from 35.2% in 2022. This growing prevalence of diabetes underscores the demand for effective solutions like afrezza.

The rise in healthcare expenditure is expected to contribute to the growth of the afrezza market. Healthcare expenditure refers to the total financial resources allocated to medical services, healthcare infrastructure, pharmaceuticals, and related activities. This expenditure is increasing due to an aging population, the growing prevalence of chronic and lifestyle-related diseases, advancements in medical technology, and expanded access to healthcare services. In the context of Afrezza, an inhaled insulin therapy, healthcare spending focuses on treatment costs, including the medication, administration devices, and monitoring, to enhance diabetes management outcomes. For instance, according to a May 2024 report from the Office for National Statistics, total healthcare expenditure in the UK increased by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% growth rate in 2022. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. This increase in healthcare investment supports the expansion of the afrezza market.

A significant trend in the afrezza market is the focus on developing technically advanced products through detailed studies on the product and its applications in diabetes management. Afrezza, which is used to manage Type 1 Diabetes with insulin inhalers, benefits from ongoing research aimed at addressing unmet needs. For instance, in June 2023, MannKind Corporation, a US-based biopharmaceutical company, initiated the INHALE-3 study. This 17-week randomized controlled trial, with a 13-week extension, aims to address critical gaps in the management of Type 1 Diabetes in adults, highlighting the commitment to innovation and improving patient outcomes.

The key players operating in the afrezza market is Mannkind Corporation.

North America was the largest region in the afrezza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the afrezza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Afrezza is an inhaled insulin medication designed to help control blood sugar levels in individuals with diabetes. As a rapid-acting insulin, it is quickly absorbed through the lungs, offering a fast-acting alternative to injectable insulin. Afrezza is primarily used to manage postprandial blood sugar spikes, which occur after meals.

The main indications for afrezza include type 1 and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition where the immune system attacks the insulin-producing beta cells in the pancreas, resulting in little or no insulin production. Afrezza is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies. Its end users include adult and geriatric patients.

The afrezza market research report is one of a series of new reports that provides afrezza market statistics, including afrezza industry global market size, regional shares, competitors with a afrezza market share, detailed afrezza market segments, market trends and opportunities, and any further data you may need to thrive in the afrezza industry. This afrezza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The afrezza market consists of sales of inhaled insulin cartridges and inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.